Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Hippocampal neurogenesis and synaptic plasticity: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 | 0.875 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna | 0.820 | Alzheimer's disease | Circuit-level neural dynamics in neurode |
| Vagal Afferent Microbial Signal Modulation | 0.621 | neurodegeneration | What are the mechanisms by which gut mic |
| Vocal Cord Neuroplasticity Stimulation | 0.515 | neurodegeneration | Digital biomarkers and AI-driven early d |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.756
neurodegeneration | 2026-04-01 | 13 hypotheses Top: 0.907
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Spp1 knockout prevents synaptic loss in AD mouse models | validation | Alzheimer's disease | 0.900 | 0.00 | Spp1 knockout AD mouse models | proposed | N/A |
| Synaptic plasticity and protein expression analysis in mPFC | exploratory | insomnia-anxiety comorbidity | 0.850 | 0.00 | mPFC brain slices from PCPA-tr | proposed | N/A |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.509 | 0.50 | human postmortem brain tissue | proposed | $520,000 |
| s:** - Test whether HCN1 knockout specifically in EC layer II accelera | falsification | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| Animal Model Comparison for Neurodegenerative Disease Therapeutics | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
| Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| tACS Connectivity Trial in Early Alzheimer's | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $730,000 |
| Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanis | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Responder Prediction Study — Precision Medicine for Neur | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechanism and Int | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propagation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Microbiome-Gut Barrier Signatures in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Microbiome-Gut-Brain Axis in Alzheimer's Disease — mechanism and inter | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Desi | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists [PMID:39865816] | Sharafshah A, Lewandrowski KU, Gold MS, | Current neuropharmacology | 2025 | 1 |
| Chemogenetic inhibition of central amygdala CRF-expressing neurons decreases alc [PMID:38509197] | ["Cruz B", "Vozella V", "Borgonetti V", | Molecular psychiatry | 2024 | 1 |
| Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling. [PMID:39737892] | ["Feetham CH", "Collabolletta V", "Worth | Nature communications | 2024 | 1 |
| Neuron type-specific optogenetic stimulation for differential stroke recovery in [PMID:38825647] | Kim RG, Cho J, Park JY, Kim YR, Lee MC, | Exp Mol Med | 2024 | 1 |
| Optogenetic control of nerve growth. [PMID:25982506] | Park S, Koppes RA, Froriep UP, Jia X, Ac | Sci Rep | 2015 | 1 |
| Antidepressant effects of combined eucommia-gastrodia extract via modulation of [PMID:41921863] | Xue L, Pan Z, Liu Y, Gan Q, Liu D, Liu D | Brain research bulletin | 2026 | 0 |
| Complementary mechanisms of high-carbohydrate diets and ketogenic diets restore [PMID:41475465] | Kwon H, Seo DS, Ahmad Y, Park S, Yoo J, | The Journal of nutritional bio | 2026 | 0 |
| TrkB promotes the neuronal secretion of soluble Siglec-2 (CD22) to mitigate micr [PMID:41922794] | Shi X, Cai SZ, Chai JL, Xu CY, Zhou BY, | Molecular psychiatry | 2026 | 0 |
| The Potential Functions and Beneficial Effects of Melatonin on Cognitive Impairm [PMID:41917799] | Li XY, Cheng YZ, Zhang YM, Hu F, Fang SK | Brain and behavior | 2026 | 0 |
| Biomarkers for Alzheimer's disease across diverse biological domains: an umbrell [PMID:40680830] | Kang J, Son Y, Yim Y, Cho H, Kim J et al | J Adv Res | 2026 | 0 |
| Nanotherapeutic potential of Baicalein-encapsulated hUC-MSC exosomes in Alzheime [PMID:41370943] | Xu J, He Z, Pan Y, Cao B, Chen G | Biomater Adv | 2026 | 0 |
| Epigenetic mechanisms and therapeutic innovations in chronic pain-associated neu [PMID:41554641] | Zhang K, Zhu S, Xing N, Zhou Z, Chen J e | Br J Pharmacol | 2026 | 0 |
| Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinfl [PMID:41570486] | Lahariya R, Anand G, Kumari B, Priyadars | J Neuroimmunol | 2026 | 0 |
| miRNA-206 in muscle and central nervous system crosstalk during exercise: A doub [PMID:41571168] | Malvandi AM, Gerosa L, Maroni P, Orlando | Neurosci Biobehav Rev | 2026 | 0 |
| Experts' narrative review "Mastication, Hippocampal Structure Changes and Cognit [PMID:41576846] | Piancino MG | Arch Oral Biol | 2026 | 0 |
| Plant-derived bioactive compounds modulate the gut microbiota in Alzheimer's dis [PMID:41678917] | Xue D, Hu X, Li R, Sun T, Qian S et al. | Phytomedicine | 2026 | 0 |
| Dysregulation of Drp1 and Mfn2 is associated with reduced PSD-95, synaptophysin, [PMID:41932483] | Alfateh M, Vasconcelos C, Choker AH, Moh | Int J Biol Macromol | 2026 | 0 |
| AICAR improves depression-like behaviors and is associated with hippocampal AMPK [PMID:41932583] | Takahashi K, Kurokawa K, Kawaguchi R, Ta | Neurochem Int | 2026 | 0 |
| Human umbilical cord mesenchymal stem cells therapy for Alzheimer's disease: a s [PMID:41847685] | Si C, Ma L, Ding W, Tian Y, Zhang J, Cao | Frontiers in neurology | 2026 | 0 |
| Optogenetic approaches for neural tissue regeneration: A review of basic optogen [PMID:39995064] | ["Eldar D", "Albert S", "Tatyana A", "Ga | Neural regeneration research | 2026 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.95 · 2026-04-06
closed · Rounds: 4 · Score: 0.95 · 2026-04-01
Hypotheses and analyses mentioning Hippocampal neurogenesis and synaptic plasticity in their description or question text
No additional research found